MARKET

CDNA

CDNA

CareDx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

62.06
-2.31
-3.58%
Opening 15:16 09/27 EDT
OPEN
64.15
PREV CLOSE
64.36
HIGH
64.36
LOW
61.95
VOLUME
449.46K
TURNOVER
--
52 WEEK HIGH
99.83
52 WEEK LOW
32.63
MARKET CAP
3.27B
P/E (TTM)
-346.4824
1D
5D
1M
3M
1Y
5Y
CareDx Presents Latest Data On AlloSeq Portfolio At ASHI 2021
CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Benzinga · 8h ago
Miromatrix Welcomes Dr. John Barry as Vice President of Research and Development
EDEN PRAIRIE, Minn., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced t...
GlobeNewswire · 09/09 12:00
Insider Sell: Caredx
MT Newswires · 09/08 11:28
3 Stocks in Cathie Wood�s ARK Genomic Revolution Fund that Wall Street Loves
StockNews.com · 09/07 13:05
10 Reddit YOLO Stocks That Are Losing Ground
In this article, we discuss the 10 Reddit YOLO stocks that are losing ground. If you want to skip our detailed analysis of these stocks, go directly to the 5 Reddit YOLO Stocks That Are Losing Ground. Retail investors have become an important market force ...
Insider Monkey · 09/04 13:07
Vera Therapeutics accelerates gains to reach over three month high
After a ~9.5% rise on Wednesday, Vera Therapeutics (NASDAQ:VERA) has added more than a tenth to its market cap so far, driving the shares to reach the highest level since
Seekingalpha · 09/02 19:10
CareDx to Participate in Upcoming Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for...
GlobeNewswire · 09/02 11:00
Is CareDx (CDNA) A Good Stock To Buy Now?
Baron Discovery Fund recently published its second-quarter commentary – a copy of which can be downloaded here. During the second quarter of 2021, the Baron Discovery Fund returned 6.07% (institutional shares). In comparison, the benchmark S&P 500 Index wa...
Insider Monkey · 09/02 05:04
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CDNA. Analyze the recent business situations of CareDx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CDNA stock price target is 107.33 with a high estimate of 118.00 and a low estimate of 100.00.
EPS
Institutional Holdings
Institutions: 339
Institutional Holdings: 63.56M
% Owned: 120.77%
Shares Outstanding: 52.63M
TypeInstitutionsShares
Increased
73
5.05M
New
48
1.59M
Decreased
103
3.76M
Sold Out
37
292.65K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.13%
Pharmaceuticals & Medical Research
-0.81%
Key Executives
Chairman/Executive Director
Peter Maag
President/Chief Executive Officer/Director
Reginald Seeto
Chief Financial Officer
Ankur Dhingra
Chief Marketing Officer
Sasha King
Vice President/Controller
Marcel Konrad
Other
Alexander Johnson
Lead Director/Independent Director
Michael Goldberg
Director
Arthur Torres
Director
Hannah Valantine
Independent Director
George Bickerstaff
Independent Director
Frederick Cohen
Independent Director
Grace Colon
Independent Director
Christine Cournoyer
Independent Director
William Hagstrom
Independent Director
Ralph Snyderman
No Data
About CDNA
CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.

Webull offers kinds of CareDx Inc stock information, including NASDAQ:CDNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CDNA stock methods without spending real money on the virtual paper trading platform.